Introduction
c-Jun N-terminal kinase (JNK) binds to the N-terminal activation domain of c-Jun and phosphorylates Ser-63 and Ser-73 leading to enhanced transcriptional activity (Pulverer et al., 1991; Adler et al., 1992; Hibi et al., 1993) . JNK is a family of enzymes encoded by three genes (Jnk1, Jnk2 and Jnk3), but alternative splicing can give rise to up to 10 JNK isoforms that differ at their Ctermini, substrate binding and tissue distribution (Derijard et al., 1994; Kyriakis et al., 1994; Gupta et al., 1996;  reviewed by Davis, 2000) . JNKs, also called stressactivated protein kinases (SAPKs), form a subfamily of the mitogen-activated protein kinases (MAPKs) that are activated by hierarchical protein kinase cascades (reviewed by Davis, 2000) . These cascades amplify and convey signals into the nucleus, so controlling the genomic response to external stimuli. JNK is activated by dual phosphorylation on a Thr-Pro-Tyr motif, catalysed by one of two MAP kinase kinases (MKKs), MKK4 and MKK7; recent data suggest that MKK4 and MKK7 exhibit a preference for phosphorylating the Tyr and Thr residues, respectively (Fleming et al., 2000; Tournier et al., 2001) . MKK4 and MKK7 are activated by phosphorylation, catalysed by one of a number of MAP kinase kinase kinases (MKKKs), including MEKK 1-4, ASK1 and MLK3. Once phosphorylated, JNK enters the nucleus where it phosphorylates c-Jun leading to activation of AP-1 and ATF/CRE enhancer elements and a corresponding transcriptional response.
The role of JNK in the stress response is complex, having been implicated in promoting both apoptosis and cell survival (reviewed by Ip and Davis, 1998; Davis, 2000) . The clearest role for JNK in promoting cell death has emerged from studies in neuronal systems. In primary sympathetic neurons and established PC12 cells, withdrawal of NGF leads to a sustained activation of JNK and a c-Jun-dependent transcriptional response, which is required for apoptosis (Estus et al., 1994; Ham et al., 1995; Xia et al., 1995) . Furthermore, Jnk3À/À mice exhibit defective apoptosis following neuro-excitatory stress (Yang et al., 1997) . Finally, primary fibroblasts derived from Jnk1À/ÀJnk2À/À embryos lack JNK activity and exhibit defective apoptotic responses to UV irradiation and chemical stresses but not to activation of Fas (Tournier et al., 2000) . These data indicate that JNK is required for the response to some, but not all, apoptotic stimuli.
Other studies have suggested that the JNK pathway may promote survival. For example, compound Jnk1À/ÀJnk2À/À mutant embryos exhibit increased apoptosis within the developing forebrain (Kuan et al., 1999; Sabapathy et al., 1999) . In addition, the JNK pathway can propagate serum-independent survival signals triggered by integrin engagement in some cell types (Almeida et al., 2000) . The consequences of JNK activation may depend upon the activation state of other coincident signalling pathways. Indeed, apoptosis following withdrawal of NGF requires activation of JNK and the concomitant inhibition of the ERK survival pathway (Xia et al., 1995) .
While JNK activation may exert different effects in different cell types, it is likely that some of the confusion surrounding the role of JNK in cell death is because few studies have been able to dissociate JNK activation from stress-induced damage or other stress-induced signal pathways. DRaf-1:ER* allows selective activation of the ERK1/2 cascade (Samuels et al., 1993) and, in combination with studies using selective 'MEK inhibitors', has allowed examination of the 'necessity' and 'sufficiency' of the ERK pathway in defined biological responses such as cell proliferation (Woods et al., 1997) . Here, we describe a conditionally active construct termed DMEKK1:ER*. Activation of DMEKK1:ER* with 4-hydroxytamoxifen (4-HT) results in the rapid, sustained and selective activation of JNK in CC139 fibroblasts. This system provides us with a means of dissecting the role of JNK in apoptosis while circumventing primary stress-induced cellular damage or other stress-induced signalling cascades. We show that sustained activation of JNK requires concomitant inhibition of the phosphoinositide 3-kinase (PI3K) survival pathway to initiate activation of Bax and apoptosis and that this death pathway does not require new protein synthesis.
Results

Characterisation of DMEKK1:ER*
We constructed a chimeric protein kinase, DMEK-K1:ER*, composed of the constitutively active kinase domain of rat MEKK1 (DMEKK1, residues 1181-1493) fused to a modified form of the estrogen receptor (ER*) and incorporating an N-terminal Myc-tag. CC139 Chinese hamster lung fibroblasts were transfected with pBP 3 -DMEKK1:ER* or the corresponding catalytically inactive mutant (DMEKK1:ER*KD) and clonal cell lines isolated. Figure 1a shows the expression of Myctagged DMEKK1:ER* in CM1.27 cells but not in the parental CC139 cells. The expression of DMEKK1:ER* increased following a 24-h exposure to 4-HT; this most likely represents 4-HT-induced stabilization as a similar increase has been observed for other ER fusions including DRaf-1:ER* (Samuels et al., 1993) and DMEKK3:ER* (Garner et al., 2002 ).
CM1.27 cells were stimulated with 100 nm 4-HT for varying lengths of time and endogenous ERK1, JNK1 and p38a were assayed by an immune-complex kinase assay, as representative members of the ERK, JNK and p38 families (Figure 1a ). JNK1 activation was apparent within 30 min, sustained for the entire duration of the time course and was sevenfold above basal after 24 h. In contrast, there was no increase in ERK1 or p38a activity in response to activation of DMEKK1:ER* (Figure 1a,  b) . In addition, blotting with phospho-specific antibodies failed to detect any change in the phosphorylation state of any p38 isoforms (Figure 7c ) or ERK2 (S Molton and S Cook, data not shown). Similar results were observed in CM1.1 cells, an additional independently derived clone, and in Rat-1 cells expressing DMEKK1:ER* (S Molton and S Cook, data not shown). A control cell line, CM1.2KD, expressing the catalytically inactive mutant DMEKK1:ER*KD (Figure 1b) did not exhibit any 4-HT-induced activation of ERK, JNK or p38 (Figure 1b) . Thus, the ability of DMEKK1:ER* to activate the JNK pathway is not an artefact of 4-HT or the CM1.27 cell line but requires the kinase activity of DMEKK1:ER*.
DMEKK1:ER* activated JNK1 in a dose-dependent fashion ( Figure 1c) ; half-maximal activation was observed at 3 nm 4-HT, agreeing well with that reported for other kinase:ER* fusions (Woods et al., 1997; Garner et al., 2002) . At high doses, we frequently observed a down-turn in the dose-response curve for JNK activation and this may be due to some form of negative feedback regulation of the pathway during prolonged stimulation. Indeed, a similar down-turn was observed in time course studies after the initial peak of JNK activation at 1 h ( Figure 1a ). While DMEKK1:ER*-induced JNK1 activation was not as great as that observed in response to UV irradiation, it was of a similar magnitude to that observed with hydrogen peroxide or anisomycin, two well-characterized SAPK pathway stress agonists, and approximately twofold greater than that observed for doxorubicin (Figure 1d ).
These results demonstrate that activation of DMEK-K1:ER* results in the rapid and selective activation of the JNK pathway in a dose-dependent manner. Rather than causing an artificially high level of JNK1 activation, DMEKK1:ER* promoted activation of JNK1 to a level similar to that seen in response to many commonly used cell stresses. Significantly, however, this activation of the JNK pathway proceeds in the absence of any primary stress or cellular damage.
Activation of DMEKK1:ER* results in phosphorylation of c-Jun but not IkBa Activation of DMEKK1:ER* in CM1.27 cells caused a marked increase in c-Jun phosphorylation when cell lysates were immunoblotted with appropriate phosphospecific antibodies (Figure 2a ). c-Jun phosphorylation was apparent after 30 min, persisted for the full 24 h of the time course and correlated precisely with the kinetics of JNK activation. Furthermore, at early time points (30 min to 3 h) activation of JNK and c-Jun phosphor-ylation were observed without DMEKK1:ER* stabilization (Figure 2a) , suggesting that at least in the first few hours, conditional derepression of the pre-existing DMEKK1:ER* is the likely mechanism by which the JNK pathway is activated.
MEKK1 has been implicated in the activation of the IKK complex that promotes phosphorylation and degradation of IkB and subsequent activation of NFkB (Lee et al., 1997 (Lee et al., , 1998 Nakano et al., 1998; Leonardi et al., 2000) . However, when CM1.27 whole-cell extracts were immunoblotted for total IkBa and phosphorylated IkBa (Ser-32 and Ser-36), we observed no increase in IkBa phosphorylation or decrease in total IkBa following activation of DMEKK1:ER*, whereas calyculin A was clearly effective. These results indicate that DMEK-K1:ER* selectively activates the JNK-c-Jun pathway, but does not promote IkB phosphorylation.
Activation of DMEKK1:ER* produces a reversible growth arrest but fails to elicit apoptosis To investigate the effects of DMEKK1:ER* activation on cellular proliferation, CM1.27, CM1.1, CM1.2KD and parental CC139 lines were treated with increasing concentrations of 4-HT in complete growth medium for 72 h before determining relative cell numbers by staining .27 cells were treated with increasing concentrations of 4-HT for 3 h. Lysates normalized for protein content were subjected to an immune-complex kinase assay for JNK1. (d) CM1.27 cells were treated for 1 h with 100 nm 4-HT, 1 mm hydrogen peroxide (H 2 O 2 ), 10 mg/ml anisomycin (Anis.), 40 mJ UV radiation (UV) (followed by 1 h recovery), ethanol vehicle control (EtOH) or 2 h with 5 mm doxorubicin (Dox.). Lysates were assayed for JNK1 as previously described. Data are expressed as fold activation over control. In all cases, similar results were obtained in at least three independent experiments for total cellular protein with crystal violet. Activation of DMEKK1:ER* inhibited proliferation of CM1.1 and CM1.27 cells by 60-70%, with half-maximal inhibition being observed at doses of approximately 5 nm 4-HT (Figure 3a) . In contrast, the catalytically inactive CM1.2KD and parental CC139 cell lines displayed no such response, confirming that growth inhibition was entirely dependent upon the kinase activity of DMEK-K1:ER* and that 4-HT exerts no toxic effects on CC139 cells. This growth arrest was found to be reversible since cell number recovered to that observed in untreated cells if 4-HT was removed and cells were washed thoroughly (Figure 3b ).
To address whether activation of DMEKK1:ER* promoted cell death, apoptosis was assessed with a panel of established assays using treatment with etoposide as a positive control. Treatment of CM1.27 cells with 100 nm 4-HT for 24 h did not cause any increase in the percentage of cells exhibiting a sub-G 1 or hypodiploid DNA content, whereas CM1.27 cells treated with etoposide were divided largely between those exhibiting sub-G 1 DNA and those with a 4n DNA content (Figure 4a, upper panel) . Activation of DMEKK1:ER* caused arrest of cells at the G 2 phase with a 4n DNA content and this may explain the inhibition in cell proliferation. Cells undergoing apoptosis typically exhibit cell shrinkage, but flow cytometric analysis of forward scatter revealed no decrease in cell size when CM1.27 cells were stimulated with 100 nm 4-HT. Indeed, there was a slight increase in cell size, which may reflect the partial G 2 arrest observed. In contrast, treatment with etoposide caused cells to either shrink in cell size due to apoptosis, or increase in cell size due to their arrest at the G 2 phase of the cell cycle ( Figure 4a , lower panel).
Flow cytometric analysis of CM1.27 cells doublestained with propidium iodide (PI) and Annexin V showed no evidence of apoptosis or necrosis following activation of DMEKK1:ER* for 24 or 48 h (Figure 4b ). In contrast, CM1.27 cells treated for 24 h with 20 mm etoposide displayed a characteristic shift into the lower Lysates normalized for protein content were subjected to SDS-PAGE followed by Western blotting using antibodies for total cJun, P-c-Jun (S63), P-c-Jun (S73) and myc (9E10). (b) CM1.27 cells were treated with 100 nm 4-HT or ethanol vehicle control over the time points indicated. CM1.27 cells treated with 25 nm Calyculin A (Cal A) for 1 h were harvested as positive controls. Lysates normalized for protein content were subjected to SDS-PAGE followed by Western blotting using antibodies for P-IkBa (S32/36) and total IkBa .27 cells were treated as described in (a) except that after fixing cultures at 72 h, duplicate plates were washed thoroughly, placed in 4-HTfree media and allowed to grow for a further 72 h. In both cases, relative cell number was analysed by measuring the absorbance of crystal violet-stained protein at 590 nm. Data are expressed as a percentage of untreated control culture growth and represent the mean7range of duplicate determinations. Similar results were obtained in three independent experiments right quadrant indicative of apoptosis. Finally, activation of DMEKK1:ER* for 24 h failed to elicit any significant increase in caspase activity, assayed using the synthetic caspase substrate Ac-DEVD-AMC (Nicholson et al., 1995;  reviewed by Cohen, 1997) , whereas etoposide caused a statistically significant 50-fold increase ( Figure 4c ). These results suggest that selective activation of the JNK pathway by DMEKK1:ER* results in a reversible inhibition of proliferation in CC139 fibroblasts but fails to induce apoptosis.
Inhibition of phosphoinositide 3
0 -kinase (PI3K) allows DMEKK1:ER* to promote death
In sympathetic neurons, cell death following withdrawal of NGF requires activation of JNK and the concomitant downregulation of ERK activity (Xia et al., 1995) . To determine if DMEKK1:ER*-induced cell death required downregulation of cell survival pathways, we performed DEVDase assays on extracts from CM1.27 cells treated for 24 h with combinations of 4-HT, the MEK-ERK pathway inhibitor U0126 (U0) and the PI3K inhibitor LY294002 (LY). No increase in DEVDase activity was seen with 4-HT, LY294002, U0126 or LY294002 þ U0126 (Figure 5a ). Similarly, activation of DMEKK1:ER* coupled with inhibition of MEK1/2 did not give rise to DEVDase activity. In contrast, inhibition of PI3K coincident with activation of DMEK-K1:ER* caused a strong, synergistic increase in DEVDase activity ( Figure 5a ).
Time-course analysis confirmed this synergistic effect. Activation of DMEKK1:ER* or treatment with LY294002 for up to 30 h resulted in little, if any, increase in DEVDase, whereas the combination of 4-HT and LY294002 resulted in activation of DEVDase activity that was nine-fold over control values by 20 h (Figure 5b, upper panel) . Immunoblots of CM1.27 cells treated in parallel confirmed these observations, revealing that significant quantities of cleaved activated caspase-3 were only detected when DMEKK1:ER* was activated in combination LY294002 (Figure 5b , lower panel). Immunoblots of total and phospho-PKB (Ser-473) confirmed that LY294002 was inhibiting PI3K and so preventing PKB phosphorylation under these conditions. This synergy between DMEKK1:ER* and LY294002 was also observed when we examined downstream markers of cell death such as the accumulation of cells with sub G 1 DNA content (Figure 5c ).
Analysis of the CM1.2KD line, expressing the catalytically inactive version of DMEKK1:ER*, showed no such synergistic effect upon addition of 4-HT and LY, although the withdrawal of serum caused a strong increase in DEVDase activity (Figure 5d ). This confirmed that the synergy between DMEKK1:ER* and LY294002 required the kinase activity of the wild-type DMEKK1:ER* and that neither LY294002 or 4-HT were effective on their own.
Some studies have recently suggested that activation of the PI3K pathway can actually inhibit JNK activation (Okubo et al., 1998; Desbois-Mouthon et al., 2000; Levresse et al., 2000) . This raised the possibility that LY294002, by inhibiting basal PI3K, was removing a constitutive inhibition of the JNK pathway, thereby boosting JNK activity to a threshold level at which it could promote apoptosis. To address this directly, we measured the activation of JNK by 4-HT, LY294002 or 4-HT þ LY294002 (Figure 5e ). The results of this analysis revealed that LY294002 alone did not increase JNK activity and, more importantly, did not potentiate DMEKK1:ER*-induced JNK activation. Thus, the synergy between DMEKK1:ER* and LY294002 for apoptosis is not due to a synergistic amplification of ; that for 4-HT was not. In all cases, a representative experiment typical of at least three others is shown JNK activity. Taken together, these results indicate that in CC139 cells, the ability of JNK to promote cell death requires concomitant inhibition of the PI3K cell survival pathway.
DMEKK1:ER* and LY294002 cooperate to induce N-terminal conformational changes in Bax
Previous studies have suggested that JNK activity is required to initiate the mitochondrial cell death pathway (Tournier et al., 2000) . To investigate the mechanism underlying the cooperation between DMEKK1:ER* and LY294002, we examined members of the Bcl-2 family of proteins, which are conserved regulators of the mitochondrial death pathway. Prosurvival Bcl-2 proteins, such as Bcl-2, Bcl-x L and Mcl-1, act by sequestering proapoptotic proteins such as Bax and Bak away from the mitochondria. Cellular stresses in turn are thought to disrupt this by activating 'BH3-only' members of the Bcl-2 family, with the result that Bax becomes activated and promotes release of apoptogenic mediators from the mitochondria. During its activation, Bax undergoes a series of conformational changes culminating in its oligomerization. One of the earliest events is a change in conformation at the N-terminus that can be monitored with the N-terminal conformation-specific N-20 antibody (Makin et al., 2001; Marani et al., 2002) .
We used the N-20 Bax antibody to immunoprecipitate native Bax from CHAPS detergent lysates and then subjected these Bax IPs to Western blot with anti-Bax antibodies. The assay was validated by the use of CHAPS lysates from untreated or etoposide-treated cells and lysates from untreated cells prepared with 1% Triton X-100, which is sufficient to expose the N-20 epitope (Figure 6a, left panel) . When CM1.27 cells were treated with 4-HT or LY294002 for up to 24 h, we did not observe any conformational activation of Bax. However, the combination of 4-HT and LY294002 did result in the accumulation of conformationally active Bax (Figure 6a, right panel) . Analysis of total cell lysates from the same samples revealed that the total level of Bax remained unchanged under these conditions. These results indicate that JNK activation and PI3K inhibition act as independent signals that synergize to initiate the activation of Bax.
We next examined the expression of both proapoptotic and prosurvival members of the Bcl-2 family. Activation of DMEKK1:ER* alone had no effect on the expression or electrophoretic mobility of Bcl-x L , Mcl-1, Bim or Bad and caused only a small decrease in Bcl-2 levels (Figure 6b) . Interestingly, although expression of the pro-death protein Bim is regulated by JNK and c-Jun in neurons (Putcha et al., 2001; Whitfield et al., 2001) , activation of the JNK/c-Jun pathway by DMEKK1:ER* was not sufficient to induce Bim expression in CC139 cells (Figure 6b , see also Weston et al., 2003) .
When DMEKK1:ER* was activated in combination with LY294002, we observed a progressive downregulation of Mcl-1 in addition to the modest decrease in Bcl-2. The downregulation of Mcl-1 is consistent with reports that its expression is regulated by the PI3K pathway (Wang et al., 1999; Kuo et al., 2001; Schubert and Duronio, 2001 ). In addition, we observed an apparent increase in electrophoretic mobility of Bcl-x L . For example, at 20 and 30 h, the upper band of the Bclx L doublet was readily apparent in 4-HT-treated cells, whereas this band was clearly reduced at the same time points with 4-HT þ LY294002 (Figure 6a ). It has been shown that phosphorylation of Bcl-2 is required for its prosurvival activity (Ito et al., 1997) and this phosphoregulated domain is shared by Bcl-x l (Chang et al., 1997) . It is therefore possible that dephosphorylation of Bcl-x L may inhibit its antiapoptotic activity. However, care should be taken with these interpretations since the role of phosphorylation of Bcl-2 itself is subject to considerable debate. For example, other studies argue that phosporylation of Bcl-2 actually inhibits the prosurvival activity of Bcl-2 (Haldar et al., 1995; Thomas et al., 2000) and additionally ERK, JNK and p38 have all been implicated as possible Bcl-2 kinases (Breitschopf et al., 2000; Fan et al., 2000; Torcia et al., 2001) .
In addition to these changes in the prosurvival Bcl-2 proteins, we observed that activation of DMEKK1:ER* in combination with LY294002 resulted in a transient accumulation of Bim EL at 10 h and a progressive increase in the electrophoretic mobility of Bad, consistent with its dephosphorylation. For example, Bad was apparent as a broad, diffuse band in control cells and did not change in response to activation of DMEKK1:ER*. However, the further addition of LY294002 caused the progressive dephosphorylation of Bad so that by 30 h it was predominantly a single band, with only a faint upper band visible (Figure 6b ). Both these effects can be attributed to PI3K inhibition alone. For example, Bim EL expression is regulated by the PI3K-PKB pathway in lymphocytes (Dijkers et al., 2000) and addition of LY294002 alone is sufficient to induce Bim EL expression in CC139 cells (Weston et al., 2003) . In addition, PKB can phosphorylate Bad and cause its sequestration by 14-3-3 proteins so the apparent dephosphorylation of Bad may contribute to the cell death response observed under these conditions.
Inhibition of protein synthesis does not inhibit, but actually accelerates, DMEKK1:ER*/LY294002-induced death
Several studies have suggested that the ability of the JNK pathway to promote apoptosis requires de novo Harvested lysates were normalized for protein content and then subjected to SDS-PAGE followed by Western blotting. Blots were probed for Bcl-x L , Bcl-2, Mcl-1, Bim and Bad gene expression and this would certainly be consistent with the major known function of JNK, which is to phosphorylate c-Jun. To address this, we sought to determine whether the apoptotic response observed upon the activation of DMEKK1:ER* in combination with LY294002 was dependent upon de novo protein synthesis.
We have recently shown the serum withdrawal induced activation of Bax and cell death is almost completely blocked by cycloheximide in CC139 cells (Weston et al, 2003) . As a starting point, we examined the effect of CHX treatment on the changes in Nterminal conformation of Bax. Cells treated with CHX or 4-HT alone failed to cause any increase in exposure of the N-20 epitope of Bax (Figure 7a ). The combination of 4-HT and LY294002 was again able to cause a slow increase in N-20 reactive Bax (Figure 7a ), as previously observed (Figure 6a ). To our surprise, we found that the inclusion of cycloheximide actually accelerated the onset of changes in Bax conformation, so that maximal exposure of the N-20 epitope was now observed after 8 h and declined again by 16 h. Control blots of wholecell lysates confirmed that the total level of Bax was unchanged under these conditions. A similar trend was observed when we assayed caspase activation (Figure 7b) . Treatment of CM1.27 cells with 4-HT or CHX caused little, if any, increase in DEVDase activity. It had already been established that LY alone does not induce DEVDase activity (Figure 5a,  b) . Stimulation of DMEKK1:ER* in the presence of CHX (4-HT þ CHX) caused a threefold transient increase in DEVDase activity after 10 h of treatment, returning to basal by 20 h. The combination of DMEKK1:ER* activation and inhibition of the PI3K pathway (4-HT þ LY) again caused a strong increase in DEVDase activity, which was evident at 10 h, peaked by 20 h and was declining at 30 h (Figure 7b ). However, like changes in Bax conformation, this delayed caspase activation was actually accelerated by CHX treatment so that maximal activation of DEVDase was observed after 10 h, and by 20 h DEVDase activity had returned to basal levels. These results were confirmed by Western immunoblot of duplicate lysates probed for cleaved caspase-3 (Figure 7c ). The combination of 4-HT and LY again caused the slow accumulation of cleaved, active caspase-3 after 20 and 30 h, but this response was greatly accelerated so as to be maximal at 10 h following further addition of CHX. These results clearly indicate that de .27 cells were treated for up to 30 h with 100 nm 4-HT and 20 mm LY or 100 nm 4-HT, 20 mm LY and 10 mg/ml CHX. Harvested lysates were normalized for protein content and then subjected to SDS-PAGE followed by Western blotting. Blots were probed for active caspase 3, total c-Jun, P-p38 (T180/Y182), p38, MEKK1, Mcl-1, Bcl-2 and Bcl-x L novo protein synthesis is not required for cell death induced by DMEKK1:ER* þ LY294002.
Control blots confirmed that the presence of CHX did not reduce the expression of the DMEKK1:ER* fusion protein (Figure 7c) . Furthermore, immunoblots for total and phospho-p38 confirmed that neither 4-HT þ LY294002 or the further addition of CHX led to p38 activation ( Figure 7c) ; indeed, if anything p38 levels declined upon addition of CHX. Similarly, Western blots for total c-Jun showed no increase in phosphorylation upon addition of CHX over and above that seen in response to 4-HT þ LY294002. Thus the acceleration of cell death by CHX is not due to activation of additional stress pathways such as p38.
Immunoblots for Bcl-2, Bcl-x L and Mcl-1 revealed a marked decrease in the levels of all three proteins upon addition of CHX. The decrease in Bcl-x L was slow and not apparent until after 20 h of treatment by which time DEVDase activity and caspase-3 activation had ceased. In contrast, the disappearance of Bcl-2 and Mcl-1 was more rapid. For example, after 10 h in the presence of CHX, nearly all Bcl-2 and Mcl-1 protein was lost, correlating well with the activation of Bax and the peak of DEVDase activity. These results confirm the efficacy of the CHX treatment at inhibiting protein synthesis and suggest that the acceleration of cell death may be due, in part, to loss of these prosurvival proteins.
Discussion
DMEKK1:ER* allows selective activation of the JNK pathway
Few studies have analysed the effect of JNK activation on cell viability in isolation from other stress-induced signalling pathways except by transient overexpression, which is prone to artefact due to nonphysiological signal strength and loss of signal pathway fidelity. Indeed, overexpression of MEKK1 was originally shown to activate the ERK1/2 pathway (Lange-Carter et al., 1993) , but subsequent studies have revealed that at modest expression levels, DMEKK1 activates JNK much more effectively than ERK1/2 (Yan et al., 1994; Xia et al., 1998) and recent studies in MEKK1À/À cells have revealed major defects in JNK activation but little or no effect on ERK or p38 activation (Yujiri et al., 1998) . Informed by these studies we constructed DMEKK1:ER* and have found that when activated by 4-HT, it promotes the activation of JNK1 but not ERK1 or p38a in cycling CC139 cells. In addition, we have recently found that DMEKK1:ER* fails to activate ERK5, further demonstrating the selectivity of this construct (M Squires and S Cook, data not shown).
Activation of JNK was rapid, sustained and coupled to phosphorylation of c-Jun, but we did not observe phosphorylation or degradation of IkBa in response to activation of DMEKK1:ER*. This may be because domains required to couple to IKK fall outside the core catalytic domain that was used in DMEKK1:ER* (Bonvin et al., 2002) . Alternatively, the ability of MEKK1 to activate NFkB signalling may also reflect overexpression since recent studies indicate that MEKK1À/À fibroblasts exhibit no defects in NFkB activation (Yujiri et al., 2000) .
DMEKK1:ER* should not be seen as a means of emulating the physiological functions of full-length MEKK1. Indeed, DMEKK1:ER* lacks the large Nterminal domain that mediates protein-protein interactions, which may affect its function (Xu and Cobb, 1997; Xia et al., 1998; Bonvin et al., 2002) . DMEKK1:ER* simply provides a method for rapidly and selectively activating the JNK pathway in the absence of cell stress. It affords advantages over other systems commonly used. For example, it provides a more rapid 'switch on' than transient or inducible systems and can function in the presence of protein synthesis inhibitors (Figure 7) . Furthermore, it can be titrated to allow fine regulation of JNK activity, so avoiding nonphysiological signal strength, one of the major pitfalls of transient overexpression. As such, it is hoped that DMEKK1:ER* will aid in analysing the functions of the JNK pathway in a variety of biological processes.
Sustained activation of JNK fails to initiate Bax activation and apoptosis unless the PI3K pathway is also inhibited Activation of DMEKK1:ER* resulted in the activation of JNK to levels similar to those attained with a variety of cellular stresses and inhibited proliferation. Cells accumulated with a 4n DNA content and future studies should aim to address the mechanism for this block and whether it accounts for the reduction in cell number. However, this growth inhibition was reversible, and analysis of six markers of apoptosis (Bax conformation, DEVDase activity, caspase-3 processing, sub-G 1 DNA, cell shrinkage and Annexin-V staining,) revealed that sustained JNK activation in CC139 cells did not cause death by necrosis or apoptosis, even though these cells were competent to die in response to serum withdrawal or etoposide.
Since these experiments were performed on cells in 10% FBS, we reasoned that any proapoptotic effect of JNK might be restrained by cell survival pathways activated by serum growth factors, as is the case in neurons following withdrawal of NGF (Xia et al., 1995) . Indeed, the combination of LY294002 and activation of DMEKK1:ER* resulted in conformational activation of Bax and a striking, synergistic increase in DEVDase activity. Significantly, LY294002 treatment did not enhance JNK activation suggesting that the reported ability of the PI3K pathway to repress JNK activation (Okubo et al., 1998; Desbois-Mouthon et al., 2000; Levresse et al., 2000) does not operate in these cells. This result also suggests that the magnitude of JNK activity induced by DMEKK1:ER* is sufficient to kill cells, but only when the PI3K cell survival pathway is inhibited. Thus, the ability of JNK to initiate Bax activation and apoptosis is normally restrained by the PI3K cell survival pathway in CC139 cells. This is, to our knowledge, the first demonstration of cooperation between JNK activation and PI3K inhibition upstream of Bax or Bak. While we have only studied CC139 cells in detail here, we have observed a similar synergy between DMEKK1:ER* and LY294002 in Rat-1 cells (S Molton and S Cook, data not shown), suggesting that the basal level of PI3K activity may well be a key determinant of the sensitivity of a given cell to JNKinduced apoptosis.
Cell death elicited by DMEKK1:ER* activation and PI3K inhibition does not require new protein synthesis Several studies have suggested that the ability of the JNK pathway to promote apoptosis requires de novo gene expression and this is consistent with the major role of JNK, namely activation of c-Jun. Activation of MEKK1 or JNK has been reported to induce apoptosis via increased expression of FasL (Faris et al., 1998; Kasibhatla et al., 1998; Le-Niculescu et al., 1999; Kolbus et al., 2000; reviewed by Pinkoski and Green, 1999) or by increased expression of the proapoptotic BH3-only protein Bim (Putcha et al., 2001; Whitfield et al., 2001) . Interestingly, expression of both Bim and FasL is repressed by the PI3K pathway. For example, inhibition of the PI3K-PKB pathway has been shown to induce activation of the FKHR-L1/FOXO3A transcription factor and expression of both FasL and Bim (Brunet et al., 1999; Dijkers et al., 2000) . We reasoned that the activation of c-Jun and FOXO3A that would result from activation of JNK in combination with LY294002 could result in a synergistic increased expression of FasL or Bim, which might contribute to the death response observed here. However, the cell death response was not inhibited by cycloheximide indicating that cell death proceeds via pre-existing components. Indeed, cycloheximide caused a striking acceleration of Bax and caspase activation so that both responses were essentially maximal by 10 rather than 20 h. Under these conditions, there was no evidence of enhanced p38 activation suggesting that the acceleration in cell death was not due to the activation of additional stress-signalling pathways. However, cycloheximide did cause an almost complete loss of Bcl-2 and Mcl-1 expression at 10 h.
Taken together, these results suggest that prosurvival proteins such as Bcl-2 and Mcl-1 act as barriers, preventing activation of Bax by the JNK pathway. It is only when these barriers are removed, in part by inhibition of PI3K or completely by blockade of protein synthesis, that the JNK pathway can now promote activation of Bax. Certainly, it is known that Bax and Bak are required for stress-induced cell death (Wei et al., 2001) . A recent study in Jnk1À/ÀJnk2À/À embryo fibroblasts, which lack JNK activity, has suggested that JNK is required for chemical stresses to promote loss of the mitochondrial membrane potential and release of cytochome c (Tournier et al., 2000) . One of the striking features of that study was that UV-induced cell death required JNK activation but did not require new gene expression suggesting that JNK-dependent disruption of the mitochondria and cell death proceeds via preexisting components. In addition, a recent study also indicates that JNK causes mitochondrial cell death independently of new protein synthesis (Aoki et al., 2002) . Our results are much more consistent with these studies and argue strongly that JNK-induced activation of Bax and subsequent cell death proceeds through the modulation of preexisting components. In common with other studies to date, the precise mechanism by which JNK activation initiates Bax activation and the mitochondrial cell death pathway remains to be defined, but one can envisage that JNK may directly phosphorylate a protein or proteins that lead to conformational changes in Bax. Certainly, a fraction of active JNK has been found to associate with mitochondria (Aoki et al., 2002) . Proteomics approaches may help to define the relevant JNK substrate(s) that acts to promote Bax activation.
In summary, DMEKK1:ER* shows promise as a conditional kinase that allows rapid and selective activation of the JNK pathway without transient overexpression or cellular stress. Our results indicate that selective, sustained activation of JNK to physiologically relevant levels can promote Bax activation and apoptosis through a cell-intrinsic pathway involving preexisting components, but only if the PI3K cell survival pathway is first inhibited. The activation state of the PI3K cell survival pathway is likely to be a key determinant of JNK-induced cell death, so it will be interesting to examine the effect of DMEKK1:ER*-induced JNK activation in cells with activating mutations in Ras or PI3K or disruption of the PTEN tumor suppressor.
Materials and methods
Materials
Cell culture reagents were purchased from Gibco Life Technologies. Superfect transfection reagent was supplied by Qiagen. LY294002, CPP32 substrate (Ac-DEVD-AMC) and Calyculin A were from Calbiochem. U0126 was purchased from Promega. [g-32 P]ATP was routinely purchased from Amersham. The following antibodies were used throughout this study: ERK1, JNK1 and p38a were prepared in house, Myc (9E10) was provided by the Babraham Monoclonal Antibody Facility; total c-Jun, phospho (Ser63) c-Jun, phospho (Ser73) c-Jun, total IkBa, phospho-(Ser32 and Ser36) IkBa, phospho-(Thr 180/Tyr182) p38 and cleaved caspase 3 (17 kDa fragment) were from Cell Signalling Technology/NEB; MEKK1 (C-22), and Bad were from Santa Cruz Biotechnology; Bcl-x L was from Pharmingen and Bim from Chemicon. Horseradish peroxidase-conjugated secondary antibodies were from Bio-Rad. Unless otherwise stated in the text, all other chemicals were purchased from Sigma and were of the highest grade available.
Plasmids
PCR oligonucleotides were used to amplify the catalytic domain of rat MEKK1 (DMEKK1, amino acids 1181-1493) from a template plasmid, pEXV-3 R-MEKK, kindly provided by Maria Ruggieri (ONYX Pharmaceuticals). The 5 0 oligonucleotide also encoded a Myc-tag sequence (MEQKLI-SEEDLD), which was introduced in-frame and upstream of the DMEKK1 sequence following PCR amplification. These oligonucleotides allowed for the introduction of a BamHI site at the 5 0 -end and an EcoRI site at the 3 0 -end of DMEKK1. The PCR fragments were cloned into respective sites within the expression vector, pBP3:hbER*, kindly provided by Martin McMahon, Mt Zion Cancer Centre, UCSF. The resulting construct, pBP 3 DMEKK1:ER*, encodes a fusion protein in which the catalytic domain of MEKK1 (DMEKK1) is fused to a modified form of the ER* that can only be activated by 4-HT (Littlewood et al., 1995) . A catalytically inactive variant, pBP 3 DMEKK1:ER*KD, was constructed by site-directed mutagenesis replacing the lysine residue (K 1253 ) in subdomain II (crucial for phospho-transfer) with methionine and the conserved upstream glycine-X-glycine motif (crucial for ATP binding) with alanine-X-alanine.
Cell culture
Stable lines of CC139 cells expressing DMEKK1:ER* or DMEKK1:ER*KD were produced by transfection with Qiagen Superfect, limiting dilution culture in 6 mg/ml puromycin and ring cloning. The resulting CM1 clones were routinely cultured in phenol-red free Dulbecco's modified Eagle medium (DMEM) supplemented with 4.5 mg/ml glucose, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mm glutamine, 10% (v/v) fetal bovine serum (FBS) and 6 mg/ml puromycin. Cells were stimulated with the indicated dose of 4-HT or the equivalent volume of ethanol (vehicle control) for the times indicated in the figure legends.
Western blotting
At the required times, cells were washed in phosphate buffered saline (PBS) and harvested on ice in lysis buffer (20 mm Tris (pH 7.5), 137 mm NaCl, 1 mm EGTA, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 1.5 mm MgCl 2 , 1mm Na 3 VO 4 , 1mm PMSF, 20 mm leupeptin, 10 mg/ml aprotinin and 50 mm NaF). Cell extracts were snap frozen, thawed and cleared by centrifugation. Supernatant protein concentrations were measured by the Bradford protein assay (Bio-Rad) and equal quantities of cell extracts were resolved by SDS-PAGE and transferred to Immobilon P membranes (Millipore). Membranes were then blocked for at least 1 h in 0.1% (v/v) Tween-20/PBS containing 5% (w/v) powdered milk before being probed with the desired antibodies (see Materials). Immunereactive proteins were visualized with the enhanced chemiluminescence (ECL) system (Amersham).
Immunecomplex MAPK/SAPK assays
Following stimulation, cells were washed in cold PBS, harvested as described above and assayed for ERK1, JNK1 and p38a as described previously (Garner et al., 2002; Weston et al., 2003) . Incorporation of [ 32 P] into respective substrates was quantified by PhosphorImager (Fuji).
Estimation of relative cell number by crystal violet staining
Cells were plated in 24-well plates at a density of 1 Â 10 4 ml À1 in complete medium. Following attachment, cells were treated with increasing doses of 4-HT for 72 h. Relative cell numbers were quantified by fixing cultures with acetic acid : methanol (1 : 3, v/v) followed by staining with 0.1% (w/v) crystal violet : PBS and solubilizing the resulting stained cells with 10% (v/v) acetic acid. Absorbance was read at 590 nm on a spectrophotometer (Cecil instruments).
Analysis of cell cycle profiles and apoptosis
Analysis of sub-G 1 DNA content and Annexin V staining by flow cytometry and DEVDase activity assays were performed as described previously (Garner et al., 2002; Weston et al., 2003) . The presence of conformationally active Bax displaying the N-20 epitope was determined by immunoprecipitation of Bax from whole-cell CHAPS lysates with the conformation specific N-20 antibody as described previously (Marani et al., 2002; Weston et al., 2003) .
Reproducibility of results and statistical analysis
All results shown are from single experiments representative of others performed three to five times in two independent clones. Where indicated, statistical analysis was by Student's t-test and P-values below 0.05 were taken as significant.
